Loading page…

Report overview

The report highlights Alligator's 2025 clinical progress toward Phase 3 development, including the final 30-month OPTIMIZE-1 read-out for mitazalimab. Following restructuring, the company had 11 employees at year-end and reported Group net sales of SEK 514 thousand. Its sustainability disclosures identify SDGs 3, 5 and 8 and emphasize ESG and DEI integration, employee engagement and patient dialogue.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Publication date: 25 March 2026
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

No standards or assurance data is available for this report.

ESG & Materiality

ESG data

Indicators available in this report:

Employees
Women on the board

No materiality data is available for this report.

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services